Member Info for Matml74

Managed was programmes Made clinigen website

Cliniport is a safe and secure online ordering platform specifically designed to help healthcare professionals and pharmaceutical/biotechnology companies enrol their patients in Early Access Programs – sometimes called Managed Access Programs or Special Access Programs – that provide access to innovative, pre-approval medicines direct from the pharmaceutical manufacturer.

See why over 14,000 physicians and pharmacists use Cliniport to source medicines. Cliniport also brings invaluable benefits to pharmaceutical/biotechnology companies by offering managed access data and product information in real time. Cliniport can also be tailored to manage your specific needs, ultimately helping you to help patients more effectively.

Sums the situation up perfectly Manifesto. Excited to see what transpired in the next few weeks. GLA

No but he did mention Avacta were in talks with other manufactures in the UK. Think this journalist jumped the gun. Would be highly surprised if ODX won't be producing the Avacta LFD.

VP, Synairgen have issued a half year report prior to the end of September ever since 2014. There should be no reason for them not to do so again this year and hopefully it will provide some forward looking statement and give details of numbers recruited on the home trial.

Jest reading through the Preparing for winter report. This may have been touched on before but bearing in mind this was published prior to July 20th results the following statement regarding treatments some of the comments now appear highly applicable to the Synairgen situation.

"A number of other trials are in progress, and only when these are reported will it be known what the efficacy and thus the demand will be and in what stage of disease the medicines may be best used.309 The long-term control of COVID-19 will require a pipeline of promising therapies."

and then....." The challenges for treatment and/or prevention of COVID-19 with respect to medicines will depend on the timely reporting of trials, licencing, evaluation and commissioning of medicines with accelerated access schemes, as well as mechanisms to deploy these nationally at pace. Part of this is in place with the Research to Access Pathway to Investigational Drugs – COVID-19 (RAPID-C19) led by the National Institute for Health Research (NIHR), NICE, MHRA, and NHS England; however, the manufacture and supply of drugs needs to be modelled in a global context, and with consideration of winter surges. In addition, a bottom up approach to operationalise commissioning decisions at pace is required, which will be more urgent in winter months with added pressures.

Early signals should accelerate negotiations with pharmaceutical companies, including generic manufacturers. Schemes, such as the six-week rolling stock (in place for no-deal Brexit) and others, should be considered to help maintain supplies while avoiding stockpiling more than is required. This may be particularly applicable to the drugs currently in trial.

Horizon scanning by bodies (e.g. RAPID-C19) can pick up on early signals to ensure a winter supply chain is in place given any modelling as described above. This needs to occur in tandem with early liaison with bodies that can facilitate expert review and ensure the operationalisation of commissioning policies (e.g. formulary committees)"
Report can be found here:
https://acmedsci.ac.uk/more/news/prepare-now-for-a-winter-covid-19-peak-warns-academy-of-medical-sciences

I think we aren't too far away from big news!

Qd, I think Synairgen have are very well connected into central government for this not to be a worry.

Prof. Stephen Holgate has had plenty of contact with Prof. Chris Whitty over the years while as Chair of the CFS/ME research collaborative. This can been found through searching their board meeting minutes.

HE also chaired the expert advisory group ‘policy report’ on ‘Preparing for challenging winter 2020/21 for the academy of medical sciences.

Tonlin, I agree it is bewildering that this treatment option is not being bought up more widely in parliament or mainstream news. I know if any of my family contract Covid over the coming months I would want this treatment available to them.

The interim results are due before Thursday so not long to wait for some news. I think much will be revealed about progression of the drug to market in them.

He didn't specify Antibody or antigen. So I presume the four candidates are Avacta, ODX/Abingdon antibody LFD, the Surescreen test (they mentioned antigen on sky interview) and Mologic (LFD).

Anyway market is massive!

Just saw this on Synairgen board. Some interesting comments abut testing and LFD's. Skip to 59:30.

https://www.youtube.com/watch?v=tSYz5emEQKg&feature=youtu.be

5m test per day! Most will be LFD's.

Agree it is another step forward. Once approved with Beckman in the US there should be significant revenues. No point selling now IMO.

In any case might as well wait now until results that should be here in early October which will provide a clearer picture on both operational and trading progress.

Topmeup, The RNS will be for results through to 30th June. I expect it will detail where the placing money was spent and hopefully shows much of it has been spent on stockpiling interferon.

The more interesting part of the update will be the operational update which will hopefully have some update on home trial numbers and pivotal trial.

Paddy, You should not fear blame for anything you post. Your research here is invaluable and appreciated by many people including myself. I highly likely would not have invested in GGP without it or put my two children's ISA allowances into this share. For both boys, they are now fascinated by gold mining and are doing their own research on the company so this has been a great education for them in many ways.

It is up to the individual to make their own decisions and live with them.

All the best and good luck.

Exactly Watching. Companies value is obviously less now that they will have a recurring revenue stream through the SKIN partnership. Affirmers work. Simple.

I am holding until news as well. Yes we would all like to hear news more quickly and yes I can't fathom why the government hasn't got an emergency approval out quickly, particularly as they new the second wave was coming. But many of these shares are now held with II's. There is still a buyer in the market loading up daily. Surprised no further TR1's have come through. The MM's have been trying everything to extract PI's shares, firstly with the drop back to 160's and this morning with the increase in share price on the sniff of positive sentiment due to Boris's statement last night.

The news will come, it will be big and it will be important in saving peoples lives this winter. HOLD AND WAIT.

Wafer, I fished the Test last week. Great way to get away from staring at the SNG share price all day! Won't be releasing any of my SNG shares either!!

yeah right...... What a pathetic attempt! Filtered.

All the prints of 10000 and 5000 shares today have been buys.

22-Sep-20 08:07:39 175.90 1,071 Sell* 172.00 180.00 1,884

Hard to tell yet Chris. Will know once the delayed trades start to get printed after 9am auction.

Not sure if I am reading your post correctly Tony but I think your 20 patients a day is an underestimation. Where did you get this number from? From the data I have seen approximately 20% of infections require hospitilisation. Worldwide this is in the 10’s of thousands unfortunately.

UpDown, Well said. Sums up my feelings perfectly. Wish the powers that be would pull their fingers out and get this drug to the people that need it ASAP. However am sure that our board are jumping through all the hoops the regulatory authorities are putting in front of them and see no reason to sell until news indicates otherwise. The daily price movements are not important right now. Just hold onto your shares until next rns.